[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340657-105":59,"doc-detail-340657-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-erbb3-and-akt-to-overcome-adaptive-resistance-in-eml4-alk-driven-non-small-cell-lung-cancer","Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer","","Fusion of EML4 and ALK produces oncogenic activity in about 5% of non-small cell lung cancer cases. Although ALK tyrosine kinase inhibitors can control EML4-ALK-positive disease, resistant clones emerge during therapy. The study profiles kinase signaling in EML4-ALK V1 and V3 models after acute lorlatinib inhibition and identifies ERBB and AKT-related phosphorylated tyrosine peptides upregulated by treatment. Dual ALK-ERBB or ALK-AKT blockade disrupts RAS/MAPK and AKT/PI3K signaling and increases apoptosis. Heregulin modulates inhibitor sensitivity, supporting ERBB3 and AKT as prevention targets.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-erbb3-and-akt-to-overcome-adaptive-resistance-in-eml4-alk-driven-non-small-cell-lung-cancer/340657/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-erbb3-and-akt-to-overcome-adaptive-resistance-in-eml4-alk-driven-non-small-cell-lung-cancer/340657.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in EML4-ALK-positive non-small cell lung cancer?","Question",{"text":112,"@type":113},"It addresses how tumors develop adaptive resistance during ALK-targeted therapy, despite initial effectiveness of ALK inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which signaling changes are identified after acute lorlatinib inhibition?",{"text":117,"@type":113},"Phosphorylated tyrosine peptides involving ERBB and AKT are upregulated after lorlatinib treatment in EML4-ALK-positive cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"How do ERBB and AKT inhibition affect resistant EML4-ALK cells?",{"text":121,"@type":113},"Dual inhibition of ALK with ERBB receptors or with AKT disrupts key signaling pathways and enhances apoptosis in EML4-ALK cancer cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340657,1790905838,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nTargeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer  \nJosephina Sampson 1 ✉, Hyun-min Ju2, Nan Zhang 1, Sharon Yeoh 1, Jene Choi2 ✉ and Richard Bayliss 1 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | The fusion event between EML4 and ALK drives a signiﬁcant oncogenic activity in 5% of non-small cell lung cancer (NSCLC) . Eventhough potent ALK-tyrosine kinase inhibitors (ALK-TKIs) are successfully used for the treatment of EML4-ALK-positive NSCLC patients, a subset of those patients eventually acquire resistance during their therapy. Here, we investigate the kinase responses in EML4-ALK V1 and V3-harbouring NSCLC cancer cells after acute inhibition with ALK TKI, lorlatinib (LOR) . Using phosphopeptide chip array and upstream kinase prediction analysis, we identiﬁed a group of phosphorylated tyrosine peptides including ERBB and AKT proteins that are upregulated upon ALK-TKI treatment in EML4-ALK-positive NSCLC cell lines. Dual inhibition of ALK and ERBB receptors or AKT disrupts RAS/MAPK and AKT/PI3K signalling pathways, and enhances apoptosis in EML4-ALK + NSCLC cancer cells. Heregulin, an ERBB3 ligand, differentially modulates the sensitivity of EML4-ALK cell lines to ALK inhibitors. We found that EML4-ALK cells made resistant to LOR are sensitive to inhibition of ERBB and AKT. These ﬁndings emphasize the important roles of AKT and ERBB3 to regulate signalling after acute LOR treatment, identifying them as potential targets that may be beneﬁcial to prevent |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| adaptive resistance to EML4-ALK-targeted therapies in NSCLC. |  |  |\n|  | Cell Death and Disease (2024)15:912; [https://doi.org/10.1038/s41419-024-07272-7](https://doi.org/10.1038/s41419-024-07272-7) |  |\n|  |  |  |\n\nINTRODUCTION  \nTargeting driver oncogenes in non-small cell lung cancer (NSCLC) has revolutionized the clinical outcomes of those patients. One of the most successful examples in lung cancer survival is seen in NSCLC patients harbouring the oncogenic fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) [1] . EML4-ALK oncogenic fusion identiﬁed in 2007 and is present in 5% of patients with NSCLC [1] . Up to 15 different variants of EML4-ALK have been discovered so far with most of them having the ALK gene breakpoint at exon 20, but various breakpoints in the EML4 gene. The most frequent EML4-ALK variants commonly found in NSCLC patients are variant 1 (V1, 43%) and variant 3 (V3, 40%) [2] . EML4 is a microtubuleassociated protein that contributes to cytoskeleton stability and chromosome congression during mitosis [3, 4] . ALK is a receptor tyrosine kinase (RTK) that activates mitogenic signals through MAPK, JAK/STAT, and PI3K/AKT signalling pathways [5–7] .  \nSince the discovery of EML4-ALK oncogenic fusion, several small molecule ALK inhibitors have been developed and approved for the treatment of ALK-positive NSCLC patients including, crizotinib (1st generation), ceritinib, alectinib, and brigatinib (2nd generation), and lorlatinib (LOR, 3rd generation) [8] . Despite the progress on the development of potent ALK inhibitors, ALK-resistant mutations such as G1202R, F1174L, L1196M, G1202R/L1196Mand G1202R/S1206Y, also known as on-target resistance, arise after ALK-tyrosine kinase inhibition (TKI) treatments with either crizotinib, ceritinib or alectinib [8] . In addition to on-target drug-  \nresistance mutations, there are several reports suggesting the involvement of (i) alternative tyrosine kinase receptors, including EGFR, KIT, and SRC,(ii) mutations in key genes such as p53, PI3KCA, YAP, and MET, and (iii) activation of key proliferation and antiapoptotic pathways [8, 9]. These are known as off-target resistance mechanisms that further complicate the development of systematic","cbCaioCtFEwmLDIz","https://ap.wps.com/l/cbCaioCtFEwmLDIz","pdf",4311328,21,"English","# Introduction\n## Driver oncogenes and ALK-targeted therapy\n## On-target and off-target resistance mechanisms\n## Adaptive signaling responses after ALK inhibition","[{\"question\":\"What problem does the study address in EML4-ALK-positive non-small cell lung cancer?\",\"answer\":\"It addresses how tumors develop adaptive resistance during ALK-targeted therapy, despite initial effectiveness of ALK inhibitors.\"},{\"question\":\"Which signaling changes are identified after acute lorlatinib inhibition?\",\"answer\":\"Phosphorylated tyrosine peptides involving ERBB and AKT are upregulated after lorlatinib treatment in EML4-ALK-positive cell lines.\"},{\"question\":\"How do ERBB and AKT inhibition affect resistant EML4-ALK cells?\",\"answer\":\"Dual inhibition of ALK with ERBB receptors or with AKT disrupts key signaling pathways and enhances apoptosis in EML4-ALK cancer cells.\"}]","Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer | PDF",1790037945,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/006c98f40acdd067bd682065d9853207.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/690b7cd4aa380ca116dd2999bbaec507.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0711593123dba6123a29997a323ea81b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c4f51021113e73bd2c011e614acc86e.webp",980,1301]